🇺🇸 FDA
Pipeline program

Plerixafor

003SCD101

Phase 2 mab completed

Quick answer

Plerixafor for Sickle Cell Disease is a Phase 2 program (mab) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).

Program details

Company
SANGAMO THERAPEUTICS, INC
Indication
Sickle Cell Disease
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials